Local anesthetic methods and kits

• US 20050165097A1
• Filed: 03/17/2005
• Published: 07/28/2005
• Est. Priority Date: 05/12/2000
• Status: Active Grant

• Current Assignee: Septodont Holding
• Original Assignee: Eckard Weber, Howard I. Katz
• Inventors: Weber, Eckard, Katz, Howard I.
• Granted Patent: US 7,261,889 B2
• Time in Patent Office: Days
• US Class Current: 514/537
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/24 having an amino or nitro group
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61P 23/02 Local anaesthetics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: Y10S 435/81 Packaged device or kit

Abstract

Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.

Claims

1-32. -32. (canceled)

33. A kit comprising a carrier having in close confinement therein two or more containers, wherein a first container contains an anesthetic agent and optionally an alpha adrenergic receptor agonist and a second container contains a unit dose of a composition, said unit dose comprising between about 0.0018 mg and about 0.45 mg phentolamine mesylate or a molar equivalent of another alpha adrenergic receptor antagonist.

34. The kit of claim 33, wherein said alpha adrenergic receptor antagonist is selected from the group consisting of phentolamine mesylate, phentolamine, phentolamine hydrochloride, tolazoline, yohimbine, rauwolscine, doxazosine, labetalol, prazosine, tetrazosine and trimazosine.

35. The kit of claim 33, wherein said anesthetic agent is selected from the group consisting of lidocaine, polocaine, etidocaine, lignocaine, xylocaine, novocaine, carbocaine, procaine, prilocaine, bupivacaine, cinchocaine, and mepivacaine.

36. The kit of claim 33, wherein said alpha adrenergic receptor agonist is selected from the group consisting of levonordefrin, epinephrine and norepinephrine.

37. The kit of claim 33, wherein said second container has a volume of between 1.6 mL and 1.8 mL.

38. The kit of claim 33, wherein said second container is a CARPULE.

39. The kit of claim 33, wherein said second container fits into a standard dental local anesthetic syringe.

40. The kit of claim 33, wherein said anesthetic agent and said alpha adrenergic receptor agonist are in said first container.

41. The kit of claim 40, wherein said anesthetic agent and said alpha adrenergic agonist are in separate containers.

42. The kit of claim 33, wherein said unit dose comprises between about 0.09 mg and about 0.45 mg phentolamine mesylate or a molar equivalent of another alpha adrenergic receptor antagonist.

43. A kit comprising a carrier having in close confinement therein two or more containers, wherein a first container contains an anesthetic agent and optionally an alpha adrenergic receptor agonist and a second container contains a solution comprising an alpha adrenergic receptor antagonist at a concentration of from about 0.001 mg/mL to about 0.25 mg/mL.

44. The kit of claim 43, wherein said alpha adrenergic receptor antagonist is selected from the group consisting of phentolamine mesylate, phentolamine, phentolamine hydrochloride, tolazoline, yohimbine, rauwolscine, doxazosine, labetalol, prazosine, tetrazosine and trimazosine.

45. The kit of claim 43, wherein said anesthetic agent is selected from the group consisting of lidocaine, polocaine, etidocaine, lignocaine, xylocaine, novocaine, carbocaine, procaine, prilocaine, bupivacaine, cinchocaine, and mepivacaine.

46. The kit of claim 43, wherein said alpha adrenergic receptor agonist is selected from the group consisting of levonordefrin, epinephrine and norepinephrine.

47. The kit of claim 43, wherein said second container has a volume of between 1.6 mL and 1.8 mL.

48. The kit of claim 43, wherein said second container is a CARPULE.

49. The kit of claim 43, wherein said anesthetic agent and said alpha adrenergic receptor agonist are in said first container.

50. The kit of claim 43, wherein said anesthetic agent and said alpha adrenergic agonist are in separate containers.

51. The kit of claim 43, wherein said alpha adrenergic receptor antagonist is present at a concentration of about 0.05 mg/mL to about 0.25 mg/mL.

52. The kit of claim 43, wherein said alpha adrenergic receptor antagonist is present at a concentration of about 0.25 mg/mL.

53. The kit of claim 43, wherein said second container comprises a dose of an alpha adrenergic receptor antagonist of between about 0.0018 mg to about 0.45 mg.

54. The kit of claim 53, wherein said dose is between about 0.09 mg to about 0.45 mg.